文献速递细菌感染、耐药与抗菌药物

多重耐药革兰阴性菌感染的治疗:英国抗菌化疗学会/医疗感染学会/英国感染协会联合工作组报告

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

联合工作组针对多重耐药革兰阴性菌感染的治疗,在抗菌药物处方方面提出100余条表格化推荐并建议进一步研究,同时给出医院和社区尿路感染抗菌药物使用算法。指南基于系统综述、专家意见和公开咨询制定,系统综述方法符合NICE要求及SIGN 50手册,采用AGREE II进行批判性评价。

要点

  • 工作组提出100余条针对多重耐药革兰阴性菌感染抗菌药物处方的表格化推荐,并建议进一步研究。
  • 对碳青霉烯类耐药的肠杆菌科细菌应紧急检测碳青霉烯类最低抑菌浓度并鉴定碳青霉烯酶类别。
  • 所有诊疗场所应实施抗菌药物管理项目,并以耐药率和指南依从性审核为基础。

核心结论

  • 该指南连同感染控制措施可用于遏制多重耐药菌增加并改善此类菌株感染的治疗结局。
  • 预期使用者包括医疗、科研、护理、抗菌药物药学及辅助医疗人员,可按本地情况调整使用。

研究设计与样本

  • 联合工作组报告,系统综述方法符合NICE要求及SIGN 50手册,采用AGREE II进行批判性评价,证据来自当前同行评议文献和专家意见并经过公开咨询。

主要发现

  • 支持治疗方案的优质对照随机临床试验非常少,尤其是已上市的老药。
  • 多重耐药国际定义复杂且不令人满意,妨碍改进项目的设定与监测,工作组给出了多重耐药的新定义。
  • 对背景信息、机制、全球传播及英国抗生素处方与耐药患病率进行了系统综述。

关键数值与推荐

  • 对碳青霉烯类耐药的肠杆菌科细菌应紧急检测碳青霉烯类最低抑菌浓度,并鉴定任何碳青霉烯酶类别。
  • 对所有解剖部位和标本中此类分离株进行强制报告将改善风险评估。
  • 黏菌素药敏试验应采用肉汤微量稀释法。
  • 所有诊疗场所应实施抗菌药物管理项目,以耐药率和指南依从性审核为基础,并辅以革兰阴性菌菌血症结局监测改善及向处方者反馈。
  • 应支持和开展抗生素使用、耐药及结局的地方和国家监测,抗生素处方指南应依据这些数据制定。

临床怎么用

  • 工作组针对多重耐药革兰阴性菌感染的抗菌药物处方提出100余条表格化推荐,并给出医院和社区尿路感染抗菌药物使用算法。
  • 应改进革兰阴性菌感染疑似和确诊病例的诊断与治疗。

局限性

  • 支持治疗方案的优质对照随机临床试验非常少,尤其是已上市的老药。
  • 多重耐药的国际定义复杂且不令人满意,妨碍改进项目的设定与监测。
  • 导致感染的多重耐药革兰阴性菌的药敏试验需要关键性增强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and community antimicrobial usage in urinary infection. The international definition of MDR is complex, unsatisfactory and hinders the setting and monitoring of improvement programmes. We give a new definition of multiresistance. The background information on the mechanisms, global spread and UK prevalence of antibiotic prescribing and resistance has been systematically reviewed. The treatment options available in hospitals using intravenous antibiotics and in primary care using oral agents have been reviewed, ending with a consideration of antibiotic stewardship and recommendations. The guidance has been derived from current peer-reviewed publications and expert opinion with open consultation. Methods for systematic review were NICE compliant and in accordance with the SIGN 50 Handbook; critical appraisal was applied using AGREE II. Published guidelines were used as part of the evidence base and to support expert consensus. The guidance includes recommendations for stakeholders (including prescribers) and antibiotic-specific recommendations. The clinical efficacy of different agents is critically reviewed. We found there are very few good-quality comparative randomized clinical trials to support treatment regimens, particularly for licensed older agents. Susceptibility testing of MDR GNB causing infection to guide treatment needs critical enhancements. Meropenem- or imipenem-resistant Enterobacteriaceae should have their carbapenem MICs tested urgently, and any carbapenemase class should be identified: mandatory reporting of these isolates from all anatomical sites and specimens would improve risk assessments. Broth microdilution methods should be adopted for colistin susceptibility testing. Antimicrobial stewardship programmes should be instituted in all care settings, based on resistance rates and audit of compliance with guidelines, but should be augmented by improved surveillance of outcome in Gram-negative bacteraemia, and feedback to prescribers. Local and national surveillance of antibiotic use, resistance and outcomes should be supported and antibiotic prescribing guidelines should be informed by these data. The diagnosis and treatment of both presumptive and confirmed cases of infection by GNB should be improved. This guidance, with infection control to arrest increases in MDR, should be used to improve the outcome of infections with such strains. Anticipated users include medical, scientific, nursing, antimicrobial pharmacy and paramedical staff where they can be adapted for local use.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018. PMID: 29514274. doi:10.1093/jac/dky027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。